BCKDHA: A Promising Drug Target and Biomarker for ALZHEIMER'S DISEASE

Target Name: BCKDHA

NCBI ID: G593

BCKDHA

BCKDHA: A Promising Drug Target and Biomarker for ALZHEIMER'S DISEASE

Alzheimer's disease is a progressive neurological disorder that affects millions of people worldwide, leading to memory loss, cognitive decline, and eventually, death. The underlying cause of Alzheimer's disease is the accumulation of neurofibrillary tangles and senile plaques in the brain, which cause the death of nerve cells. One of the key factors in the development and progression of these tangles and plaques is the production of branching-chain alpha-keto acids (BCKDHAs) in the brain.

BCKDHAs are a type of lipid molecule that accumulates in the brain due to the breakdown of fats, particularly in the brain. They are formed from the amino acids leucine and isoleucine, which are branching chains in the protein sequence. BCKDHAs have been shown to play a crucial role in the development and progression of Alzheimer's disease, and they are now considered as potential drug targets or biomarkers for the disease.

BCKDHA and its role in Alzheimer's disease

The accumulation of BCKDHAs in the brain is thought to contribute to the development and progression of Alzheimer's disease. Studies have shown that higher levels of BCKDHAs are associated with the severity of Alzheimer's disease symptoms, including cognitive decline and memory loss. Additionally, individuals with certain genetic mutations, such as ApoE4, are more likely to develop Alzheimer's disease and have higher levels of BCKDHAs in their brain.

In addition to its role in the development and progression of Alzheimer's disease, BCKDHA has also been shown to play a key role in the regulation of the immune system. Studies have shown that BCKDHAs can modulate the immune response and influence the production of immune cells that contribute to the development of Alzheimer's disease.

Targeting BCKDHA as a drug or biomarker

The potential targeting of BCKDHA as a drug or biomarker for Alzheimer's disease has led to a great deal of interest and research in this area. Researchers are exploring the use of drugs that can specifically target BCKDHAs in order to slow down or reverse the accumulation of neurofibrillary tangles and senile plaques in the brain.

One approach to targeting BCKDHA is to use small molecules that can inhibit the production or processing of BCKDHAs. Such molecules have been shown to be effective in animal models of Alzheimer's disease, and are now being tested in clinical trials. For example, a drug called BHV-3500 is currently being tested in clinical trials for the treatment of Alzheimer's disease. BHV-3500 is a small molecule that inhibits the activity of the enzyme BCKDHA, making it a potential drug or biomarker for Alzheimer's disease.

Another approach to targeting BCKDHA is to use antibodies that can specifically target the protein in BCKDHAs. Such antibodies have been shown to be effective in animal models of Alzheimer's disease, and are now being tested in clinical trials. For example, an antibody called R482 has been shown to be effective in reducing the formation of neurofibrillary tangles and senile plaques in animal models of Alzheimer's disease.

The potential of BCKDHA as a drug or biomarker for Alzheimer's disease has significant implications for the treatment of this debilitating and progressive disease. Further research is needed to fully understand the role of BCKDHA in the development and progression of Alzheimer's disease, as well as the safety and effectiveness of targeting it

Protein Name: Branched Chain Keto Acid Dehydrogenase E1 Subunit Alpha

Functions: E1 subunit of the branched-chain alpha-keto dehydrogenase complex that catalyzes both the decarboxylation of the alpha-ketoacid and the subsequent reductive acylation of the lipoyl moiety (another catalytic cofactor) that is covalently bound to E2 (PubMed:7883996). The branched-chain alpha-keto dehydrogenase complex catalyzes the overall conversion of alpha-keto acids to acyl-CoA and CO(2). It contains multiple copies of three enzymatic components: branched-chain alpha-keto acid decarboxylase (E1), lipoamide acyltransferase (E2) and lipoamide dehydrogenase (E3)

The "BCKDHA Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about BCKDHA comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets